MedTrace Logo

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

NCT07177716 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-09-17

No results posted yet for this study

Summary

This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330）versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.

Conditions

Interventions

BIOLOGICAL

LB1410

LB1410 (IV, Q2W for up to 2 years)

BIOLOGICAL

LB4330

LB4330 (IV, Q2W for 4 cycles)

DRUG

Lenvatinib

lenvatinib (oral, once daily for up to 2 years)

Sponsors & Collaborators

  • L & L Bio Co., Ltd., Ningbo, China

    lead INDUSTRY

Principal Investigators

  • Xiaohua Wu, Doctor · Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07177716 on ClinicalTrials.gov